This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Toll-like receptor 7 (TLR7)	<p>Mouse studies suggest stimulating TLR7 on plasmacytoid dendritic cells (pDCs) could help treat breast cancer. In an immune-competent breast cancer mouse model, a TLR7 ligand or the TLR7 agonist SM360320 activated pDCs and caused tumor regression, whereas vehicle did not. The mice also were protected from subsequent challenges with murine mammary tumor cells for at least three months after pDC stimulation. Next steps could include analyzing the immunological effects resulting from pDC activation. SM360320 is a research reagent.</p> <p>Meda AB and Valeant Pharmaceuticals International Inc. market the TLR7-targeting immune response modulator Aldara imiquimod to treat basal cell carcinoma (BCC). Telormedix S.A.'s TLR7 agonist TMX-102 is in Phase II testing to treat bladder cancer. The company's TLR7 agonist TMX-202 is in preclinical development for skin and bladder cancers.</p> <p>Idera Pharmaceuticals Inc.'s IMO-4200, a dual agonist of TLR7 and TLR8, is in preclinical development for lymphoma.</p> <p>SciBX 6(27); doi:10.1038/scibx.2013.678 Published online July 18, 2013</p>	Patent and licensing status unavailable	<p>Le Mercier, I. <i>et al. Cancer Res.</i>; published online May 30, 2013; doi:10.1158/0008-5472.CAN-12-3058</p> <p>Contact: Nadege Goutagny, Cancer Research Center of Lyon, University of Lyon, Lyon, France e-mail: nadege.goutagny@lyon.unicancer.fr</p>